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ﺍﻟﺴﺠﻞﺍﻹﻟﻜﺘﺮﻭﻧﻲﻟﻸﻣﺮﺍﺽﻳﺘﻀﻤﻦﺟﻤﻌﺎﻣﻨﺘﻈﻤﺎﻟﻠﺒﻴﺎﻧﺎﺕﺣﻮﻝﻣﺮﺽﺃﻭ
ﻣﺠﻤﻮﻋﺔﺃﻣﺮﺍﺽ.ﻫﻨﺎﻙﺭﻏﺒﺔﻟﺪﻯﻣﺠﺘﻤﻊﺍﻟﻤﺨﺘﺼﻴﻦﺑﺄﻣﺮﺍﺽﺍﻟﺠﻬﺎﺯﺍﻟﻬﻀﻤﻲ
ﻟﺘﻄﻮﻳﺮﺍﻟﺴﺠﻞﺍﻟﺸﺎﻣﻞﻟﻤﺮﺿﻰﺩﺍﺀﺍﻷﻣﻌﺎﺀﺍﻻﻟﺘﻬﺎﺑﻲﻟﺴﻨﻮﺍﺕﻋﺪﺓ.ﻭﻣﻊﺫﻟﻚﻟﻢ
ﻳﻜﻦﻫﻨﺎﻙﻋﻤﻞﻭﻃﻨﻲﻣﻨﺴﻖﻟﺘﺤﻘﻴﻖﻫﺬﺍﺍﻟﻬﺪﻑ.ﺗﺴﺘﻌﺮﺽﻫﺬﻩﺍﻟﻤﻘﺎﻟﺔﺩﻭﺍﻓﻊ
ﺗﺄﺳﻴﺲﻫﺬﺍﺍﻟﺴﺠﻞﻭﺗﻘﺘﺮﺡﻃﺮﻳﻘﺔﻣﻨﻬﺠﻴﺔﻟﻠﻌﻤﻞﻭﻃﺮﻕﺍﻟﻤﺤﺎﻓﻈﺔﻋﻠﻰ
ﺍﺳﺘﻤﺮﺍﺭﻳﺘﻪ.
ﺍﻟﻜﻠﻤﺎﺕﺍﻟﻤﻔﺘﺎﺣﻴﺔ:ﺩﺍﺀﻛﺮﻭﻥ؛ﺩﺍﺀﺍﻷﻣﻌﺎﺀﺍﻻﻟﺘﻬﺎﺑﻲ؛ﺍﻟﺘﻬﺎﺏﺍﻟﻘﻮﻟﻮﻥﺍﻟﺘﻘﺮﺣﻲ
Abstract
A registry is a systematic collection of data about a dis-
ease or a group of diseases. For some years there has been
a desire amongst the gastroenterology community to
develop a comprehensive registry of patients with in-
flammatory bowel disease (IBD). However, no coordi-
nated national approach has been developed to achieve
this objective. This article reviews the possible reasons for
establishing an IBD registry and suggests a methodo-
logical approach to achieving this goal and strategies to
maintain its continuity.* Corresponding address: Room 220, Grove Building, College of
Medicine, Swansea University, Swansea SA2 8PP, UK.
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For some years, there has been a desire amongst the
gastroenterology community to develop a comprehensive
registry of patients with inflammatory bowel disease (IBD) to
monitor patients’ responses to treatment.
Review of previous IBD registries worldwide
Several registries of biological therapy in Crohn’s disease
were commercially funded, including the TREAT Registry
for Infliximab sponsored by Schring-Plough1 and the
Registry Study for Adalimumab sponsored by Abbott.2
The problem with commercially funded registries is that
they are only run for a period of time as part of the post-
marketing phase of clinical trials. To allow for an accurate
analysis of treatment response, registries should include pa-
tients treated with biologics and those treated convention-
ally. The Rotherham IBD management software was
designed by Prof KD Bradhan to hold a large database on
the management of IBD patients. It was been developed and
supported by Ferring pharmaceuticals.3 However, many
gastroenterologists found that maintaining the database
was too time-consuming and difficult.3 An Austrian
database called the Inflammatory Bowel Diseasehis is an open access article under the CC BY-NC-ND license
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L. Alrubaiy et al.374Information System (IBDIS)4 has received growing
publicity. The aim of the IBDIS is to recruit patients for
clinical trials. However, the IBDIS collects a large number
of items for each patient. Therefore, the IBDIS is not
suitable for use in day-to-day care of individual patients in
busy outpatient clinics. In the Kingdom of Saudi Arabia, a
few hospitals have participated in a promising local IBD
registry in an attempt to examine the disease distribution and
prevalence there.5,6 The British Society of Paediatric
Gastroenterology Hepatology and Nutrition (BSPGHN)
established a registry of paediatric IBD in the late 1990s7;
however, it was only maintained for a few years.
There has been a renewed interest and impetus for the
development of an IBD registry since the second round of the
UK IBD audit and the launch in Feb 2009 of the National
IBD Service Standards,8 which strongly recommended the
establishment of such a registry to monitor the safety and
efficacy of biological therapies.9,10,11
Another element that encouraged the development of the
IBD registry was the licensing of the first anti-tumour ne-
crosis factor a (anti-TNF-a) drug, infliximab, at the begin-
ning of the last decade. The long-term outcomes of patients
treated with anti-TNF-a drugs are still unknown, and they
have a number of safety issues. Therefore, the National
Institute for Health and Clinical Excellence (NICE) in the
UK has recommended the establishment of a registry to
gather more information about the safety and efficacy of
anti-TNF-a drugs in the treatment of IBD.12,13
Examples of successful registries for anti-TNF-a drugs
have been established in the UK, Sweden, Germany, Spain,
Norway, Denmark, the Netherlands and Switzerland.14,15
The British Society of Rheumatology (BSR) established a
highly successful registry of rheumatology patients
treated with biological therapies.16,17 The French
developed a registry to identify cases of lymphoma and
infection associated with the administration of biological
therapies for any condition.18 Several biological registries
were launched to monitor the safety and efficacy of these
agents in the treatment of psoriasis.19e21 The first UK-
wide registry for IBD was launched in 2013 to promote
an agreed upon, standardised method of data collection
and to maintain properly governed access and analysis of
that data.
Benefits of the IBD registry;
The IBD registry will accomplish the following:
1. Provide national statistics on IBD patients throughout the
UK.
2. Allow local IBD units to compare their performance with
other units in the UK.
3. Monitor patient outcomes, safety and adverse events after
treatment with immunosuppressive drugs and surgery.
4. Provide a good resource for clinical governance, such as
clinical audits, prospective research, performance moni-
toring, appraisal and revalidation.
Steps in developing an IBD registry:
Developing an IBD registry involves a few steps. The first
step is to define the scope and purpose of the registry. This
will help define the data required for the registry. The data
to be obtained can include both mandatory and optional
items. A flexible registry that can adapt to clinicians’ needsin daily clinical practice will encourage healthcare pro-
fessionals to use the registry. The second step of the process
is to develop the IT infrastructure for the registry. Partici-
pating hospitals can collect and view their data, but data for
national collection and analysis will be anonymised and
held separately. Local outputs, such as individual history
summaries and outpatient letters will provide support for
day-to-day patient care. The third step includes imple-
menting the registry at the participating sites and encour-
aging healthcare professionals to use the registry in their
day-to-day care.
There are a few factors that should be considered when
implementing an IBD registry to ensure its continuity:
1. Healthcare professionals should be allowed enough time
to use the registry and to enter their data. While the value
of the IBD registry may be appreciated, entering the data
can be “too time consuming”.
2. Ideally the registry should be able to link with hospital
patient information, including administrative, laboratory,
imaging, and endoscopy details. This will avoid duplicate
data entries.
3. The registry should be easy to use, “user-friendly”, and
relevant to patient care with demonstrable benefits to the
users.
4. Users prefer a structured format with a minimal need for
free text, including, for example, “tick boxes” and “drop
down” lists for entering data. This speeds data entry and,
thus, aids in prospective data collection.
5. IBD specialist nurses are the most capable of entering
patients’ details into the registry because of their skills and
knowledge. However, the time required for this task
should be acknowledged and provided.
Summary
In summary, having a successful IBD registry will ensure
efficient patient monitoring and follow-up. It will also sup-
port data collection for audit and research purposes. How-
ever, any registry should be tailored for individual users’
needs to ensure their engagement and participation. A few
difficulties associated with establishing a country-wide IBD
registry include a lack of clinician participation or interest,
costs related to establishing and maintaining the registry,
providing sufficient time for clinicians to use the registry and
data quality assurance.Conflict of interest
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